# Protopanaxadiol stimulates glucose consumption by modulating the AMP-activated protein kinase pathway in myotubes, hepatoma cells, and adipocytes

**Authors:** Dahae Lee, Sang Hee Shim, Ki Sung Kang

PMC · DOI: 10.1371/journal.pone.0328486 · PLOS One · 2025-07-29

## TL;DR

Protopanaxadiol (PPD) from ginseng may help reduce obesity and diabetes by boosting glucose use in key body tissues.

## Contribution

PPD is shown to stimulate glucose consumption via AMP-activated protein kinase pathway modulation in multiple cell types.

## Key findings

- PPD inhibits lipid accumulation in HepG2 cells induced by palmitic acid.
- PPD enhances glucose consumption in C2C12 myotubes and 3T3-L1 adipocytes.
- PPD prevents PA-induced changes in key signaling proteins like AMPK and Akt.

## Abstract

Ginsenosides, the main active constituents of Panax ginseng, possess potent anti-diabetic and anti-obesity properties. In this study, we investigated the molecular and cellular mechanisms underlying the effects of protopanaxadiol (PPD), Rg3, Rb2, Re, Rc, Rh2, Rb1, Rg1, and compound K on palmitic acid (PA)-induced lipid accumulation in HepG2 hepatoma cells and glucose consumption (GC) in C2C12 myotubes and 3T3-L1 adipocytes. PA-induced lipid accumulation was determined using lipid (Oil Red O) staining. GC was performed using a 2-deoxy glucose based colorimetric GC kit. Protein expression was examined by western blot analysis. PPD, Rg1, Rb2, and Rg3 inhibited lipid accumulation in PA-treated HepG2 cells. PA significantly decreased lipid levels in HepG2 cells, which was prevented by PPD, Rg1, Rb2, and Rg3. PPD, Re, Rb1, and compound K enhanced PA-induced GC inhibition in 3T3-L1 cells, while PPD, Rg3, Rc, and Rh2 enhanced PA-induced GC inhibition in C2C12 cells. PA also significantly decreased the phospho-phosphoinositide 3-kinase, phospho-Akt, phospho- AMP-activated protein kinase α, and phospho-glycogen synthase kinase-3β levels as well as increased glycogen synthase, glucose-6-phosphatase, and phosphoenolpyruvate carboxykinase phosphorylation in all three cell lines, which were prevented by PPD. PPD may be a potential drug candidate that can stimulate GC in key insulin-sensitive tissues, such as the skeletal muscle, liver, and adipose tissue.

## Linked entities

- **Proteins:** AKT1 (AKT serine/threonine kinase 1), PCK1 (phosphoenolpyruvate carboxykinase 1)
- **Chemicals:** protopanaxadiol (PubChem CID 9920281), Rg3 (PubChem CID 169408342), Rb2 (PubChem CID 146350069), Re (PubChem CID 23947), Rc (PubChem CID 9943513), Rb1 (PubChem CID 736494), Rg1 (PubChem CID 441923), compound K (PubChem CID 9852086), palmitic acid (PubChem CID 985), 2-deoxy glucose (PubChem CID 108223)
- **Diseases:** diabetes (MONDO:0005015), obesity (MONDO:0011122)

## Full-text entities

- **Genes:** Pepc (peptidase C) [NCBI Gene 109616] {aka Dip-1, Pep-3, Pep3}, Rb1 (RB transcriptional corepressor 1) [NCBI Gene 19645] {aka Rb, Rb-1, p110-RB1, pRb, pp105}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, CCN6 (cellular communication network factor 6) [NCBI Gene 8838] {aka LIBC, PPAC, PPD, PPRD, WISP-3, WISP3}, Gc (vitamin D binding protein) [NCBI Gene 14473] {aka DBP, VDB}, Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, Pck1 (phosphoenolpyruvate carboxykinase 1, cytosolic) [NCBI Gene 18534] {aka PEPCK, PEPCK-C, Pck-1}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, PEPC (peptidase C) [NCBI Gene 5183], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, IRS1 (insulin receptor substrate 1) [NCBI Gene 3667] {aka HIRS-1}, Irs1 (insulin receptor substrate 1) [NCBI Gene 16367] {aka G972R, IRS-1}, G6PC1 (glucose-6-phosphatase catalytic subunit 1) [NCBI Gene 2538] {aka G6PC, G6PT, G6Pase, GSD1, GSD1a}, PCK1 (phosphoenolpyruvate carboxykinase 1) [NCBI Gene 5105] {aka PCKDC, PEPCK-C, PEPCK1, PEPCKC}, GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932], Rbl2 (RB transcriptional corepressor like 2) [NCBI Gene 19651] {aka PRB2, RBR-2, Rb2, p130}, G6pc1 (glucose-6-phosphatase catalytic subunit 1) [NCBI Gene 14377] {aka G6Pase, G6pc, G6pt, Glc-6-Pase}, RB1 (RB transcriptional corepressor 1) [NCBI Gene 5925] {aka OSRC, PPP1R130, RB, p105-Rb, p110-RB1, pRb}, Gsk3b (glycogen synthase kinase 3 beta) [NCBI Gene 56637] {aka 7330414F15Rik, 8430431H08Rik, GSK-3, GSK-3beta, GSK3}, PRKAA2 (protein kinase AMP-activated catalytic subunit alpha 2) [NCBI Gene 5563] {aka AMPK, AMPK2, AMPKa2, PRKAA}
- **Diseases:** T2D (MESH:D003924), cytotoxicity (MESH:D064420), resistant (MESH:D060467), bone loss (MESH:D001847), impaired glucose metabolism (MESH:D044882), weight gain (MESH:D015430), diabetic (MESH:D003920), retinopathy (MESH:D058437), dyslipidemia (MESH:D050171), obesity (MESH:D009765), IR (MESH:D007333), fluid retention (MESH:D016055), hepatic injury (MESH:D056486), lipid overload (MESH:D011017), hypoglycemia (MESH:D007003), cardiovascular diseases (MESH:D002318), GC (MESH:D014397), hepatoma (MESH:D006528)
- **Chemicals:** Compound K (MESH:C112772), Ez-Cytox reagent (-), metformin (MESH:D008687), Glucose (MESH:D005947), saline (MESH:D012965), penicillin (MESH:D010406), 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl) amino)-2-Deoxyglucose (MESH:C098340), 1-methyl-3-isobutylxanthine (MESH:D015056), isopropyl alcohol (MESH:D019840), Glycogen (MESH:D006003), PPD (MESH:C062916), PVDF (MESH:C024865), Ginsenosides Rg3 (MESH:C097367), thiazolidinedione (MESH:C089946), CO2 (MESH:D002245), streptomycin (MESH:D013307), Ginsenosides (MESH:D036145), Saturated fatty acids (MESH:D005227), DMSO (MESH:D004121), DW (MESH:D014867), dexamethasone (MESH:D003907), PA (MESH:D019308), free fatty acid (MESH:D005230), Rosiglitazone (MESH:D000077154), Re (MESH:D012211), oil (MESH:D009821), 2-deoxy glucose (MESH:D003847), lipid (MESH:D008055), ORO (MESH:C011049), SDS (MESH:D012967), paraformaldehyde (MESH:C003043)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Panax ginseng (Asiatic ginseng, species) [taxon 4054], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Cell lines:** ATCC CRL-1772 — Homo sapiens (Human), 5' 10' methylenetetrahydrofolate reductase deficiency, Finite cell line (CVCL_B3VW), HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027), ATCC CL-173 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), 3T3 L1 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0123), HepG2 hepatoma — Mus musculus (Mouse), Hepatocellular carcinoma of the mouse, Cancer cell line (CVCL_H613), C2C12 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0188)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12306732/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12306732/full.md

## References

39 references — full list in the complete paper: https://tomesphere.com/paper/PMC12306732/full.md

---
Source: https://tomesphere.com/paper/PMC12306732